DVA is now DaVita Labs

NewsGuard 100/100 Score

Operating as a division of DaVita Inc. (NYSE: DVA), a leading provider of kidney care services for those diagnosed with end stage renal disease (ESRD) and chronic kidney disease (CKD), DVA Laboratory Services (DVA) announced its new company name, DaVita Labs.

With over a decade of existence and the support of more than 120,000 kidney patents nationwide, DaVita LabsSM has provided diagnostic laboratory services to both dialysis organizations and physician practices. As DaVita Inc. continues to prove its commitment to the laboratory business, the decision has been made to unify the brand under one name, resulting in DaVita Labs. Though the name has changed, DaVita Labs will continue to provide the same reputable services to serve its customers with a relentless pursuit of quality.

"The decision to unify DVA Laboratory Services under the DaVita name will add to the continuity and full-service offerings our companies collectively provide," stated DaVita Labs Vice President, Commercial Development Kevin J. Goudreau. "We feel the name change will better reflect the unified network and corporate identity of the DaVita Inc. brand."

The new name initiative for DaVita Labs was launched at the American Nephrology Nurses' Association (ANNA) 42nd National Symposium, which took place March 27-30, 2011 in Boston.

DaVita Labs has 86,700 square feet dedicated to its state-of-the-art clinical diagnostic laboratories between its two locations in Ft. Lauderdale and Deland, Florida. The laboratories feature the latest in renal-specific methodology and technology for delivering quality test results. The DaVita Labs clinical laboratory team is led by experienced scientists and pathologists, and receives formal guidance from top nephrologists in the industry.

DaVita and DaVita Labs are trademarks or registered trademarks of DaVita Inc. All other trademarks are the property of their respective owners.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Phase 3 trial shows overall survival benefit from adjuvant therapy in kidney cancer patients